Stereotaxis Inc

Stereotaxis Inc(STXS)股票分析

$1.450

-0.020 (-1.36%)收盤時

Loading chart…
High
1.490
Open
1.480
VWAP
1.46
Vol
289.61K
Mkt Cap
145.45M
Low
1.440
Amount
422.83K
EV/EBITDA, TTM
-4.71

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, it offers its customers x-ray systems and other accessory devices. It also provides robotic technologies for interventional cardiology and neuro-interventions. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters.

AI analysis of Stereotaxis Inc (STXS)

buy

Stereotaxis Inc. is a good buy right now due to its current price of $1.45, which is significantly lower than the average analyst price target of $3. Additionally, the company has shown a gross margin improvement to 60.31% in Q1 2026, indicating better cost management and profitability potential. The main risk is the net loss of $4.78 million reported in Q2 2026, which highlights ongoing financial challenges.

Analyst Ratings (1)

+189.66% upside
Hold
0 Buy
1 Hold
0 Sell
Current: 1.45
最低
4.00
平均
4.20
最高
5.00

Citizens

2026-08-27

目標價

$3

Outperform

Lake Street

2026-08-12

目標價

$3

Buy

TD Cowen

2026-08-12

目標價

$3

Buy

Piper Sandler

2026-05-13

目標價

$4

Overweight

Citizens

2025-12-16

目標價

$4

Outperform

估值指標

The current forward P/E ratio for Stereotaxis Inc (STXS) is 19.65, compared to its 5-year average forward P/E of -8.10.

Forward P/E

Strongly Overvalued
5Y Average P/E
-8.10
Current P/E
19.65
高估
5.08
低估
-21.28

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-22.35
Current EV/EBITDA
-4.71
高估
-4.29
低估
-40.41

Forward P/S

Undervalued
5Y Average P/S
5.57
Current P/S
2.76
高估
8.14
低估
3.01

Alphio AI Price Scenarios for STXS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%STXS

$2.82

情境價格

B

Base

Base · 50%STXS

$2.64

情境價格

B

Bear

Bear · 25%STXS

$2.55

情境價格

事件時間軸

2026-08-11 (ET)

16:30:00

Stereotaxis Q2 Revenue at $7.67M, Below Consensus

2026-07-15 (ET)

20:00:00

Apple Stock Hits Record High Above $325

17:30:00

Stereotaxis Files to Sell 108.87M Shares of Common Stock

17:30:00

Stereotaxis Files to Sell 19.45M Shares of Common Stock

2026-04-15 (ET)

07:10:00

Stereotaxis Acquires Robocath for $20 Million

資訊

STXS FAQ — answered by Alphio AI

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, it offers its customers x-ray systems and other accessory devices. It also provides robotic technologies for interventional cardiology and neuro-interventions. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Stereotaxis Inc. is a good buy right now due to its current price of $1.45, which is significantly lower than the average analyst price target of $3. Additionally, the company has shown a gross margin improvement to 60.31% in Q1 2026, indicating better cost management and profitability potential. The main risk is the net loss of $4.78 million reported in Q2 2026, which highlights ongoing financial challenges.

1 analysts cover STXS: 0 rate it Buy, 1 Hold and 0 Sell. The average price target is 4.20.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始